The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -58.42%.However, over the last six months, we can see a stronger performance of -68.73%. Over the last 30 days, the price of ZNTL has leaped by -0.79%. And in the last five days, it has fallen by 0.00%.
Zentalis Pharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $13.00 on 05/31/24 and the lowest value was $1.01 on 04/09/25.
52-week price history of ZNTL Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Zentalis Pharmaceuticals Inc’s current trading price is -90.31% away from its 52-week high, while its distance from the 52-week low is 24.75%. The stock’s price range during this period has varied between$1.01 and $13.00. The Zentalis Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.61 million for the day, a figure considerably lower than their average daily volume of 0.86 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Zentalis Pharmaceuticals Inc (ZNTL) has experienced a quarterly decline of -48.15% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 90.49M and boasts a workforce of 166 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.9554, with a change in price of -1.6550. Similarly, Zentalis Pharmaceuticals Inc recorded 1,418,461 in trading volume during the last 100 days, posting a change of -56.78%.
ZNTL’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ZNTL stands at 0.13. Similarly, the long-term debt-to-equity ratio is also 0.13.
ZNTL Stock Stochastic Average
Zentalis Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 24.88%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 24.69%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 10.83% and 14.20%, respectively.
